Form 4: Gilead Sciences CFO Andrew Dickinson Executes Stock Options and Sells Shares Under 10b5-1 Plan

Andrew Dickinson, CFO of Gilead Sciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 12, 2025, Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, executed non-qualified stock options to acquire common stock at prices of $63.91, $57.92, $80.72, and $83.49.
• He acquired 77,691 shares at $63.91, 26,175 shares at $57.92, 15,600 shares at $80.72, and 18,210 shares at $83.49.
• Following the acquisition of these shares, Dickinson sold 137,676 shares of common stock at a price of $102.22.
• After these transactions, Dickinson directly owns 171,223 shares of Gilead Sciences common stock.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which is a common practice. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry where insider information can significantly impact stock prices. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options to align management's interests with those of shareholders.
• The vesting schedules and exercise prices of these options are typically benchmarked against industry peers to ensure competitiveness.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector, such as Amgen, Pfizer, and Johnson & Johnson, to manage their stock holdings in a compliant manner.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, but the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Gilead Sciences, Andrew Dickinson, CFO, Stock Options, Form 4, Rule 10b5-1, Insider Trading, GILD, Share Sale